1. Evaluation of efficacy and safety of AAV8-ΔC4ATP7B gene therapy in a mutant mouse model of Wilson’s disease
- Author
-
Chunhua Zeng, Yunting Lin, Xinshuo Lu, Shehong Chen, Yan Xia, Kangdi Zhang, Yongxian Shao, Zhihong Guan, Rong Du, Zongcai Liu, Mingqi Zhao, Xiaoling Jiang, Yanna Cai, Taolin Li, Xueying Su, Yaoyong Chen, Xiaoyan Dong, Wen Zhang, Li Liu, and Wenhao Zhou
- Subjects
AAV8 ,ΔC4ATP7B ,gene therapy ,Wilson’s disease ,copper ,liver disease ,Genetics ,QH426-470 ,Cytology ,QH573-671 - Abstract
Wilson’s disease (WD) is an autosomal recessive disorder caused by pathogenic variants in the ATP7B gene, resulting in the toxic accumulation of copper (Cu). Impaired Cu homeostasis in WD is characterized by low serum ceruloplasmin, excess hepatic Cu, and elevated urinary Cu. WD often presents with hepatic and/or neurological diseases and is fatal if untreated. Adeno-associated virus (AAV)-mediated gene therapy holds promise for WD, but challenges remain in efficacy and safety. Here, we established an Atp7b R780L knockin (KI) mouse model corresponding to the human ATP7B R778L variant and investigated the therapeutic efficacy and safety of liver-targeted AAV8-mediated ATP7B (AAV8-ΔC4ATP7B) gene therapy in this model. The results demonstrated the Atp7bKI/KI mice recapitulated key features of impaired Cu metabolism in WD but had mild liver disease. Ten-week-old Atp7bKI/KI mice received a single-dose of AAV8-ΔC4ATP7B and were sacrificed at 8 or 30 weeks after treatment. Treated Atp7bKI/KI mice showed normalization of serum ceruloplasmin, reduced hepatic Cu, decreased urinary Cu, and reversed liver histopathology. Serum transaminases had a transient increase at 8 weeks after treatment but returned to normal at 30 weeks after treatment. These data provide evidence for the efficacy and safety of AAV8-ΔC4ATP7B in animals, supporting clinical translation to patients with WD.
- Published
- 2025
- Full Text
- View/download PDF